NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

心臟標記分析儀市場預測(2021年∼2026年)

Cardiac Market Analyzer Market - Forecasts from 2021 to 2026

出版商 Knowledge Sourcing Intelligence 商品編碼 1023165
出版日期 內容資訊 英文 115 Pages
商品交期: 最快1-2個工作天內
價格
心臟標記分析儀市場預測(2021年∼2026年) Cardiac Market Analyzer Market - Forecasts from 2021 to 2026
出版日期: 2021年07月06日內容資訊: 英文 115 Pages
簡介

全球心臟標記分析儀市場規模在2019年估算為14億3,871萬3,000美元。2026年達到19億773萬6,000美元,今後市場在2019年∼2026年的預測期間內,預計將以4.11%的年複合成長率成長。心血管疾病和死亡人數上升是嚴重問題,政府正在加大對醫療領域的投資。此次投資的增加有望擴大心臟標記分析儀行業的市場規模。

本報告提供全球心臟標記分析儀市場的相關調查,提供市場動態,市場分析,競爭環境與分析,企業簡介等全面性資訊。

目錄

第1章 簡介

  • 市場定義
  • 市場區隔

第2章 調查手法

  • 調查資料
  • 假設

第3章 摘要整理

  • 調查的重點

第4章 市場動態

  • 市場推動因素
  • 市場阻礙因素
  • 波特的五力分析
    • 供應商談判力
    • 買方議價能力
    • 替代品的威脅
    • 新加入企業的威脅
    • 產業的競爭企業間的敵對關係
  • 產業的價值鏈分析

第5章 心臟標記分析儀市場:各心臟標記

  • 簡介
  • 肌鈣蛋白
  • 肌酸激酶
  • 肌紅蛋白
  • 其他

第6章 心臟標記分析儀市場:各終端用戶

  • 簡介
  • 醫院及診療所
  • 研究所
  • 門診病人手術中心

第7章 心臟標記分析儀市場:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 其他
  • 中東及非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 台灣
    • 泰國
    • 印尼
    • 日本
    • 其他

第8章 競爭環境與分析

  • 主要企業策略分析
  • 新興企業與市場賺
  • 合併,收購,協定,及合作
  • 供應商競爭力矩陣

第9章 企業簡介

  • Radiometer Medical ApS
  • Ardiogenics Inc
  • F. Hoffman-La Roche Ltd.
  • Abbott
  • Beckman Coulter Inc.
  • Siemens Healthcare Private Limited
目錄
Product Code: KSI061610969

The cardiac marker analyzer market is projected to grow at a CAGR of 4.11% during the forecast period to reach US$1,907.736 million by 2026 from US$1,438.713 million in 2019. Rising instances of cardiovascular diseases and increasing death due to them are the prime reason driving the market growth of cardiac marker analyzers during the forecasted period. According to data provided by the World Health Organization, cardiovascular diseases are the leading cause of death globally. Annually, WHO estimates that 17.9 million people die due to cardiovascular diseases (CVD), which accounts for 30% to 31% of global deaths. 85% of CVD deaths occur due to heart attacks and strokes, while 45% of these deaths occur in lower- and middle-income countries. Hectic lifestyle, heavy workload, and disturbed meal cycles have increases stress and are becoming the leading reason for the rise in cardiovascular diseases among adults.

Growing CVD and deaths has raised severe concerns and increased investment in the healthcare sector by the government. Increased investment is anticipated to raise the market size of the cardiac marker analyzer industry.

Cardiac marker significance in the healthcare sector, particularly cardiac troponin, will provide a stable market for cardiac marker analyzers during the forecasted period.

In the healthcare industry, cardiac markers are used to diagnose acute coronary syndrome (ACS) or any other CVD in case the patient is suffering from chest pain or other problems. Cardiac markers are used to locate potential CVD so that timely treatment can save a person's life and keep them healthy. Rising CVD cases and deaths have increased the adoption of these markers in hospitals and clinics for prior detection and early treatment of the patient. Hence, with rising healthcare infrastructure development, a cardiac marker will play a crucial role in the healthcare industry for better diagnosis, with promising market stability.

Among varied cardiac markers, cardiac troponin is anticipated to dominate the market owing to its efficiency and effectiveness in the detection of CVDs. Research from the Heart Org states that cardiac troponin is the prime choice of cardiac marker among patients suffering from ACS. Troponin is based on guidelines of the European Society of Cardiology (ESC) and the American College of Cardiology (ACC) and hence is widely accepted around the world. Troponin earned this recognition owing to superior sensitivity and accuracy in detection. Moreover, these markers provide faster results than other modes.

Rising government expenditure on the healthcare sector will boost the market demand for cardiac marker analyzer.

Increasing investment by the government around the world, in the healthcare sector, will support the market growth of cardiac markers analyzers during the forecasted period. Rising instances of CVDs and other diseases have raised serious concerns which lead to fuelling of the healthcare sector with funds for modern technology for diagnosis and treatment to save lives. Hence it is anticipated that expenditure on cardiac markers technology will also increase at a significant level. Further, technological advancement and automation in the sector will increase the market prospects during the forecasted period. Globally, the average healthcare expenditure is on a rise, increasing from US$ 914.203 per capita in 2010 to US$ 1,110.841 per capita in 2018.

Governments are as well increasing their expenditure for better healthcare and standard of living. The US government is anticipated to increase expenditure from 17.7% of GDP in 2019 to 19.1% by 2028 (source: CMS). The Indian government has also increased the healthcare budget from 1.5% of GDP in 2020-21 to 1.8% of GDP in 2021-22 Union Budget. Furthermore, increasing expenditure on technological advancement and automation will drive the market up, tapping new opportunities. The Japanese government, for example, has invested US$100 million in the development of healthcare and social robots. Similarly, the South Korean government invested US$ 250 million in the innovation of healthcare, rehabilitation, and disaster management robots.

A rise in medical tourism will drive the demand for Asia pacific cardiac marker analyzer market.

On geographical bifurcation, the Asia Pacific region is projected to show exponential growth during the forecasted period. The prime reason driving the growth in this region is the availability of affordable medical services which has significantly increased medical tourism in the region. The Asian region has low-cost but high-quality medial services which are affordable for the general public, particularly in the American and European region. Hence, the region has attracted foreign patients for better medical treatments, raising the demand for medical equipment for effective diagnosis and treatments, driving the market size of cardiac markers. Furthermore, increasing expenditure by the government sector and the emergence of private players have provided a vast market for the industry.

Covid Insights.

The coronavirus pandemic positively affected the global cardiac marker analyzer market. To contain the outbreak of the virus, the healthcare sector was fuelled with investment for better treatment of both, covid and non-covid infected persons. Further, the rise in CVD cases and deaths increased more concerns which increased investment for CVD diagnosis and treatment, increasing the industry scope.

Market Segmentation:

  • By Cardia Marker
  • Troponin
  • Creatine Kinase
  • Myoglobin
  • Others
  • By End-User
  • Hospitals and Clinics
  • Laboratories
  • Ambulatory Surgical centers
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Others
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Thailand
  • Taiwan
  • Indonesia
  • Others

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Powers of Buyers
    • 4.3.3. Threat of Substitutes
    • 4.3.4. The threat of New Entrants
    • 4.3.5. Competitive Rivalry in Industry
  • 4.4. Industry Value Chain Analysis

5. Cardiac Marker Analyzer Market, by Cardiac Marker

  • 5.1. Introduction
  • 5.2. Troponin
  • 5.3. Creatine Kinase
  • 5.4. Myoglobin
  • 5.5. Others

6. Cardiac Marker Analyzer Market, by End-Users

  • 6.1. Introduction
  • 6.2. Hospitals and Clinics
  • 6.3. Laboratories
  • 6.4. Ambulatory Surgical Centers

7. Cardiac Marker Analyzer Market, by Geography

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. United States
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. Germany
    • 7.4.2. France
    • 7.4.3. United Kingdom
    • 7.4.4. Spain
    • 7.4.5. Others
  • 7.5. The Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. UAE
    • 7.5.3. Israel
    • 7.5.4. Others
  • 7.6. Asia Pacific
    • 7.6.1. China
    • 7.6.2. India
    • 7.6.3. South Korea
    • 7.6.4. Taiwan
    • 7.6.5. Thailand
    • 7.6.6. Indonesia
    • 7.6.7. Japan
    • 7.6.8. Others

8. Competitive Environment and Analysis

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Emerging Players and Market Lucrative
  • 8.3. Mergers, Acquisition, Agreements, and Collaborations
  • 8.4. Vendor Competitiveness Matrix

9. Company Profiles

  • 9.1. Radiometer Medical ApS
  • 9.2. Ardiogenics Inc
  • 9.3. F. Hoffman - La Roche Ltd.
  • 9.4. Abbott
  • 9.5. Beckman Coulter Inc.
  • 9.6. Siemens Healthcare Private Limited